Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05949957
Other study ID # 2023/00178
Secondary ID 2023/00178
Status Recruiting
Phase N/A
First received
Last updated
Start date October 20, 2023
Est. completion date December 3, 2028

Study information

Verified date November 2023
Source Singapore Institute for Clinical Sciences
Contact Johan Ericksson, MD
Phone 6516 4079/ 8938 7374
Email Johan_eriksson@sics.a-star.edu.sg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Women with Gestational Diabetes Mellitus (GDM) are 12-times more likely to develop Type 2 Diabetes (T2D) 4-6 years after delivery than women without GDM. There has been evidence that lifestyle modifications such as physical activity (PA), dietary intake, sleep, and stress management can prevent or delay type 2 diabetes (T2D). The purpose of this study is to assess the efficacy of a holistic lifestyle digital health intervention with post-GDM women in large community settings in Singapore. The study consists of a 1-year randomized controlled trial (RCT) with 3 years follow-up. Women who are eligible for the study will be randomized to either Group 1 (Intervention) or Group 2 (Control) at baseline. Both groups will be followed in years 2-4. Women from both groups will be provided with an Oura ring for tracking physical activity, sleep, and heart rate variability (a proxy for stress), and the "HAPPY app," which will provide health promotion information about physical activity, diet, sleep, and mental wellbeing, as well as display the information collected (such as body mass index, blood pressure, and OGTT results). The active group will receive the "LVL UP app" a smartphone-based chatbot-delivered intervention, designed to provide personalized recommendations through multiple digital coaching sessions aimed at improving health literacy and practicing healthy lifestyles to prevent Type 2 diabetes and common mental disorders (i.e., anxiety, depression).


Description:

The overall goal of this study is to reduce the risk of Type 2 diabetes (T2D) and pre-diabetes in Asian women and their children by focusing upon a major high-risk group - women with a history of gestational diabetes (GDM) in Singapore. GDM is diabetes diagnosed for the first-time during pregnancy and has traditionally been considered a benign condition because typically glucose levels return to normal after delivery. Women with pregnancies complicated by GDM often progress to develop T2D later in life. There is evidence that holistic lifestyle modifications that include strategies to improve dietary intake, physical activity, and mental well-being can prevent or delay the onset of type 2 diabetes. The use of digital health interventions can also assist in the prevention of T2D. However, limited studies have been conducted with Asian populations. This study aims (1) to identify post-GDM women from large community settings in Singapore and to assess the efficacy of a holistic lifestyle digital intervention (focusing on diet, physical activity, sleep, and mental well-being) on glucose regulation with those identified women. Secondary objectives are: (a) to examine the potential impacts of the proposed intervention on the health and well-being of subjects' family members (e.g., children); (b) to determine the diabetes risk of the subjects over a 3-year follow-up period; (c) to explore potential economic impacts of the proposed intervention (e.g., healthcare expenditures); (d) to study the importance of gut microbiota and epigenetic factors in relation to changes in glucose metabolism, and (e) to ascertain the safety of the proposed intervention. The study is a 1-year randomized controlled trial with three years of follow-up. The primary outcomes involved the incidence of Type 2 diabetes confirmed by a 2-hr 75g Oral Glucose Tolerance Test (OGTT) over a 4-year period. Secondary outcomes are (1) incidence of impaired fasting glucose and impaired glucose tolerance; (b) changes in cardiometabolic variables (e.g., body weight, HbA1c, insulin, blood lipids, blood pressures) in the women; (c) changes in women's body composition; (d) changes in women's mental well-being (e.g., defined by BDI-II, STAI, WHO-5, PSS-4); (e) changes in the health and wellbeing of their children, and (f) a composite of major adverse events (MAE) comprising fatal and non-fatal events associated with Type 2 diabetes. Eligible women will be randomized at baseline to either Group 1 (Intervention) or Group 2 (Control) for 1 year. Group 1 (Intervention) consists of several virtual coaching sessions about healthy lifestyle delivered by a conversational agent (chatbot) embedded in the LvL UP App within 24 weeks (weeks 2 to 26) to complete three levels of health literacy. Additionally, individuals will receive an Oura ring at baseline (activity-tracking wearable that collects lifestyle data), as well as the HAPPY App (educational content about lifestyle and health outcomes [e.g., body mass index, blood pressure, OGTT results]). Group 2 (Control) subjects will receive an Oura ring at baseline, and the HAPPY App Follow-up Period Upon completion of the one-year RCT period, both groups will be followed-up for 3 years. During the follow-up visits, body measurements, OGTT, bio-sampling, and data collection will be conducted. Both groups will be assessed at baseline, week 26, 1 year visit, 2-year visit (follow-up 1), 3-year visit (follow-up 2), and 4-year visit (follow-up 3)


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date December 3, 2028
Est. primary completion date December 3, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 21 Years to 45 Years
Eligibility Inclusion Criteria: 1. Female, age: 21 - 45 years 2. Had a history of GDM (at least 1 year and not more than 10 years) 3. Chinese, Malay or Indian ethnic groups 4. Body mass index (at least 18.5 kg/m2 and not more than 35 kg/m2) 5. Not planning to conceive in the next one year 6. Not performing exclusive breastfeeding during study period 7. Own a smartphone compatible with the study mobile Apps 8. Proficient in English language 9. Plan to stay in Singapore for the next 4 years 10. Willing to comply to study protocol 11. Able to provide a written informed consent Exclusion Criteria: 1. Current or previous diagnosis of diabetes (Type 1 or 2), except GDM 2. Currently pregnant 3. Given birth within the last 12 weeks 4. Severely limited mobility (e.g., wheelchair bound, require long-term walking aid, etc.) 5. Diagnosed with malnutrition or eating disorder 6. Diagnosed with cancers, unstable heart diseases, severe kidney diseases, severe liver diseases 7. Diagnosed with severe insomnia, unstable mental conditions, dementia, or cognitive impairment 8. Experienced alcohol or drug abuse 9. Currently having medications known to influence glucose metabolism (e.g. peroral corticosteroids) 10. Currently participating in concurrent clinical trial or lifestyle intervention study

Study Design


Intervention

Behavioral:
LvL UP App
LvL UP App: A Smartphone-based conversational agent-delivered holistic lifestyle intervention. The intervention group will receive several digital coaching sessions focus on 3 pillars: diet, physical activity, and mental well-being to promote health literacy and promote healthy lifestyles. The app includes practical exercises per pillar (e.g., journaling, slow-breathing exercises, lifehacks).
HAPPY App
HAPPY App: Each subject will use the HAPPY App that aims to:(1) deliver health promotion information (guided by Singapore Health Promotion Board's resources), and (2) display health data collected (e.g., body mass index, blood pressure, OGTT results) that help them monitor own health and prevent T2D.
Oura Ring And Oura App
Oura ring and Oura App: Each subject will receive an Oura ring, i.e., an activity-tracking wearable that collects lifestyle data (physical activity, sleep and heart rate (as a proxy for stress) that will be synced with Oura App

Locations

Country Name City State
Singapore Singapore Institute for Clinical Sciences (SICS) Singapore

Sponsors (1)

Lead Sponsor Collaborator
Singapore Institute for Clinical Sciences

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Other Cognitive emotion regulation strategies CERQ: Cognitive Emotion Regulation Questionnaire Baseline, Week 26 (Midpoint Visit), Year1
Other Sleep wake up MEQ:The morningness-eveningness questionnaire Baseline, Week 26 (Midpoint Visit), Year1
Other Happiness SHS: Subjective Happiness Scale Baseline, Week 26 (Midpoint Visit), Year1
Other Health Literacy HLQ: Health Literacy Questionnaire Baseline, Week 26 (Midpoint Visit), Year1
Other Stress PSS-4: Perceived Stress Scale 4 Baseline, Week 26 (Midpoint Visit), Year1
Other Mental Wellbeing WHO-5 wellbeing Index Baseline, Week 26 (Midpoint Visit), Year1
Other Infant sleep BISQ-R-SF: Brief infant sleep questionnaire is on parent-reported toddler (0-3 years) sleep over prior 1 week. Baseline, year 1
Other Child and Mother Interaction StimQ-toddler (for age 1-3 years) / StimQ-pre-school (for age 4-5 years) is designed to find out the different types of toys and games that mothers have for child in the home, and the kinds of activities that mother and child do together. 12 months (Year 1 visit)
Other Child's Sleep Habits CSHQ: Child's Sleep Habits Questionnaire (for age 4-5 years) assesses the frequency of children behaviors associated with common pediatric sleep difficulties. Baseline, year 1
Primary Glucose Tolerance Changes 2-hr 75g Oral Glucose Tolerance Test (OGTT) Changes in glucose over four years, including: Baseline, Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Anthropometric Measurements Participants will be measured for their height in feet and weight in kilograms. Weight and height will be combined to report BMI in kg/m^2. Baseline, Week 26/27 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Blood pressure (BP) Blood pressure will be measured using an automated blood pressure monitor. Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Biosample Collection (Fasting blood) Fasting blood draw will be analyzed for HbA1c & fasting blood glucose Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Biosample Collection (Saliva) Saliva collected using Salivette® kit (cortisol) Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Biosample Collection (Buccal swab) Buccal swab collected using Isohelix kit (DNA profiling) Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Biosample Collection (Stool) Stool collected via OMNIgene®•GUT OM-200 (Gut microbiota) Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Bioelectrical Impedance Analysis (BIA) BIA is a non-invasive technology that can accurately measure a person's total body water, extracellular and intracellular fluid volumes. Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Depression Beck Depression Inventory II (BDI-II) Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Anxiety The State-Trait Anxiety Inventory (STAI) Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Health Status The Short Form (36) Health Survey (SF-36) Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Sleep PSQI: The Pittsburgh Sleep Quality Index (PSQI Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Lifestyle e-Diary (Qualtrics survey system) self-report lifestyle Baseline, Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
Secondary Social-emotional development (Children) ASQ:-3: Ages and stages questionnaire: social-emotional development screening tool is used to assess children's (for age 2 month - 60 months) self-regulation, communication, autonomy, compliance, adaptive functioning, affect, and interaction with people. Baseline, Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3)
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A